PART I . Overview We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutic...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076742 | EDGAR | 100K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034176 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-021656 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-007053 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004724 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269596 | EDGAR | 22K words |
| 2025-07-31 | 2025-06-30 | 0000950170-25-100925 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066387 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123391 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095753 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055681 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058248 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038057 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017907 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024192 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016893 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009955 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-076612 | EDGAR | 3K words |
| 2026-01-29 | 0001193125-26-028186 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009854 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269548 | EDGAR | — |
| 2025-10-31 | 0001104659-25-104696 | EDGAR | — |
| 2025-10-29 | 0001104659-25-103726 | EDGAR | — |
| 2025-09-04 | 0000950170-25-112973 | EDGAR | — |
| 2025-07-31 | 0000950170-25-100902 | EDGAR | — |
| 2025-06-16 | 0000950170-25-086830 | EDGAR | — |
| 2025-05-27 | 0001104659-25-052719 | EDGAR | — |
145 total filings indexed. 118 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001813814 |
| Ticker | DFTX |
| Exchange | Nasdaq |
| SIC | 2833: Medicinal Chemicals & Botanical Products |
| Incorporated | A1 |
| Website | https://www.definiumtx.com |
| Listed | 2020-03-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report